SMS Pharmaceuticals Limited — Important, 12-02-2025: Financial Result Updates

**Consolidated Financial Summary**

For the quarter ended 31st December 2024, SMS Pharmaceuticals Limited reported consolidated revenues of ₹17,548.14 crore, reflecting a growth of approximately 7.67% compared to ₹16,297.30 crore in the same quarter last year. Key drivers for this revenue increase may include rising demand for Active Pharmaceutical Ingredients and improved operational efficiencies.

Net profit for the period amounted to ₹1,824.17 crore, up from ₹1,148.03 crore year-over-year, translating to an Earnings Per Share (EPS) of ₹2.15. This significant profit increase can be attributed to better cost management and a reduction in operational expenses, despite the rising cost of materials consumed.

Total expenses rose to ₹15,304.26 crore, primarily driven by increases in manufacturing and employee-related costs. The overall operational efficiency was affected by changes in inventory which saw a notable swing.

The balance sheet shows total reserves of ₹52,786.37 crore, indicating a solid capital position, while cash flow remains stable, ensuring continued operational flexibility.

Strategically, SMS Pharmaceuticals appears focused on enhancing efficiencies and managing costs effectively amidst growing market opportunities. The market sentiment remains positive, given the robust profit margins and revenue growth potential.

**Investor Insight:** Given the strong earnings trajectory and improving operational metrics, a prudent strategy would be to consider accumulating shares for long-term growth, while monitoring market conditions and potential cost challenges.